INTRODUCTION:

An intestinal condition that is characterized by chronic inflammation and dysregulated intestinal homeostasis is known as inflammatory bowel disease (IBD). IBD can manifest clinically in two different waysany area of the digestive system might be impacted by the condition Crohn's disease (CD). and ulcerative colitis (UC), which only affects the colon.¹ In actuality, a thorough understanding of the precise process that causes the disease is still unknown². Heat shock proteins are widely expressed molecules that cause stress. That are highly conserved inall eukaryotic cells. These proteins are traditionally divided into six major families based on their molecular mass, with members ranging in size from 10 to 170 kDa.^3.-4. Inflammatory cells of the lamina propria of healthy gastric and colonic mucosa as well as gastric epithelial cells express. Heat shock protein32 in a constitutive manner. Regardless of whether the stomach mucosa was infected with H pylori, there was an upregulation of HSP32 expression in the inflammatory colon, especially in patients with UC.

These findings support the theory that enhanced mucosal formation of reactive oxygen metabolites and other inflammatory mediators in inflamed gut mucosa could trigger local synthesis of HSP32 since HSP32 is generated by oxidative stress. According to recent findings, the mitochondrial chaperonin⁵. Shared epitopes between human HSP32 and HSP60 from several intestinal pathogenic bacteria resulted in "molecular mimicry," which eventually leads to interactivity and the development of autoimmune. Furthermore, earlier research has shown thatcomparing IBD patients to healthy individuals reveals that HSP60 levels are higher in the lamina propria of the colon.⁶. These findings suggest that HSP60 may be involved in inducing inflammatory responses. According to this conclusion, giving 5-aminosalicylic acid (5-ASA) alone or in combination with probiotics to IBD patients reduced inflammation while also lowering HSP60 expression levels⁷, every organ and cell, including the intestine, have the chaperonin component known as Hsp60.both mitochondrial inside and outside, are its orthodox practices, it plays significant roles in cellular physiology.⁸The Hsp60 chaperonopathies, which may include IBD, are a variety of disorders in which Hsp60 can also be pathogenic.⁹ Itis conceivablea possible major event driver and may have etiopathogenic potential function among the complex mix of causal elements that contribute to the many clinic-pathological kinds of IBD. Hsp60 is a biomarker that can help in IBD illness diagnosis.¹⁰

METHOD:

50 samples from patients with inflammatory bowel disease (IBD) who visited Al-Hilla Teaching Hospital and Marjan Hospital for both sexes were collected for this investigation. Ages 20 to 70 were represented by 30 samples of women and 20 samples of males. These individuals had blood extracted from them using a wine syringe, which was then centrifuged after being placed in a tube. An ELISA equipment was used to collect the serum and quantify the levels of HSP32 and HSP60.

RESULTS:

Figure 1: show male and female percentage in patients with IBD.

Table 1: Values Hsp32 in patients and control with IBD

Age group	patient	control
20-30	27.3333±6.65833	10.3333±3.51188
30-40	73.0000±7.00000	47.6667±7.09460
40-50	144.6667±11.06044	109.6667±8.73689
50-60	228.0000±5.56776	175.3333±5.03322
60-70	262.0000±13.11488	158.3333±118.24692

LSD=6

Table 2: valuesHsp60in patients and control

Age group	patient	control
20-30	14.0000±4.58258	2.1333±2.48462
30-40	32.0000±2.00000	23.3333±4.16333
40-50	52.3333±2.51661	42.6667±5.13160
50-60	71.6667±3.51188	63.3333±3.05505
60-70	90.0000±3.00000	80.0000±2.00000

LSD=4

DISCUSSIONS:

The phrase (IBD) designates a group of autoimmune, chronic, and etiologically unidentified disorders, including Crohn's disease (CD) and ulcerative colitis (UC).Additionally, it exhibits signs that are progressive and could be incapacitating.¹¹ higher than females, reaching 62%, compared to males, reaching 44%. this results identical to the research¹² and¹³yet. This study does not agreewith the researches¹⁴who found that males and females were evenlyinfluenced. Other studies have shown that the percentage of females is greater than that of males¹⁵Heat shock proteins (Hsps) are widely distributed and highly conserved intracellular proteins. Although they are distinguished by their ability to respond to a quick increase in temperature, they are also produced in vitro by a range of other physiological stresses such as inflammatory cytokines and mediators.¹⁶ Although earlier reports show induction of Hsp32 (HO-1) in the gastrointestinal mucosa of rats with experimentalgastric ulceration and colitis.¹⁷Induced by reactive oxygen metabolites (ROM), heat shock protein 32 (Hsp32, hemoxygenase-1) breaks down heme and produces the antioxidant bilirubin. With inflammatory bowel illness and gastritis, there is an increase in ROM mucosal formation. In this research, the level of HSP32 was measured in this research, the level of hsp32 was measured, as its concentration increased in different age groups compared to healthy people, and the highest concentration reached in the age group )60-70) years reach 262.0000±13.11488 compared to control 158.3333±118.24692.this study suit with the studies¹⁸. We observe that hsp32 concentration rises with aging. Cappello along with his coworkers listed various factorsproving this assertion, including the importance of HSP60 in the etiology of IBD and its treatment. These include (a) HSP60's ability to activate pro-inflammatory cytokines. HSP60 is relevant in other inflammatory conditions such atherosclerosis, (b) the fluctuation in HSP60 levels in UC mucosa in response to the disease status, (c) and (d) the ability of HSP60 to block pro-inflammatory cytokines.. Hsp60 concentration was evaluated as it rose with age in comparison to healthy individuals. The highest concentration was found in the age group of 60 to 70 years, reaching 90.0000 3.00000 compared to control 80.0000 2.00000. This research fits with previous research.¹⁹

REFERENCES:

1. Prerna Dubey, Sumithra. M, Chitra. V. Assessment of Inflammatory Bowel Disease and its Herbal Cure: A Review. Research J. Pharm. and Tech. 2019; 12(3): 1432-1440. doi: 10.5958/0974-360X.2019.00238.5

2. Prajapati KV, Jain VC, Prajapati N. Pharmacology of combined Mesalazine and Rifaximin Therapy to Inflammatory Bowel Disease. Asian J Pharm Tech. 2016; 6(1): 45-50.

3. Dhole AR, Shendage GG, Pethkar S, Magdum CS, Mohite SK. Drug used in Inflammatory Bowel Disease (IBD)-Brief Review. Research J Pharmacology Pharmacodynamics. 2014; 6(3): 153-161.

4. S.G.R.G. Barton, D.S. Rampton, V.R. Winrow, P. Domizio, and R.M. Feakins. Expression of heat shock protein 32 (hemoxygenase-1) in the normal andinflamed human stomach and colon:an immunohistochemical study. Cell Stress and Chaperones. 2003; 8(4): 329–334

5. Susmi M S, Revathy S Kumar, Sreelakshmi V, Sruthy V Menon, Surya Mohan, SaranyaTulasidharanSuja, Sathianarayanan, Asha AsokanManakadan. A Computational approach for identification of Phytochemicals for targeting and optimizing the inhibitors of Heat shock proteins. Research J. Pharm. and Tech. 2015; 8(9): 1199-1204. doi: 10.5958/0974-360X.2015.00219.X.

6. K. N. Anitha, K. M. Geetha. Soluble Epoxide Hydrolase: A Pharmaceutical Target for Inflammation. Research J. Pharm. and Tech. 2019; 12(10):5113-5118. doi: 10.5958/0974-360X.2019.00886.2.

7. C. Barbatis, M. Tsopanomichalou. Heat Shock Proteins in InflammatoryBowel Disease. J. Annals of Gastroenterology. 2009; 22(4): 244-247

8. Rohitas Deshmukh. Development and In‑Vitro Evaluation of Colon Specific Indomethacin Matrix Tablet for the Treatment of Inflammatory Bowel Disease. Research Journal of Pharmacy and Technology. 2021; 14(5):2391-6. doi: 10.52711/0974-360X.2021.00422

9. Cappello, F.; Mazzola, M.; Jurjus, A.; Zeenny, M.-N.; Jurjus, R.; Carini, F.; Leone, A.; Bonaventura, G.;Tomasello, G.; Bucchieri, F.; et al. Hsp60 as a Novel Target in IBD Management: A Prospect. Front. Pharmacol. 2019, 10, 26.

10. Sangiorgi, C.; Vallese, D.; Gnemmi, I.; Bucchieri, F.; Balbi, B.; Brun, P.; Leone, A.; Giordano, A.; Conway deMacario, E.; Macario, A.J.L.; et al. HSP60 activity on human bronchial epithelial cells. Int. J. Immunopathol. Pharmacol. 2017, 30, 333–340.

11. Rodolico, V.; Tomasello, G.; Zerilli, M.; Martorana, A.; Pitruzzella, A.; Gammazza, A.M.; David, S.; Zummo, G.;Damiani, P.; Accomando, S.; et al. Hsp 60 and Hsp10 increase in colon mucosa of Crohn’s disease andulcerative colitis. Cell Stress Chaperones. 2010; 15: 877–884.

12. Rohitas Deshmukh, SujataKumari, Ranjit K. Harwansh. Inflammatory Bowel Disease: A Snapshot of Current Knowledge. Research J. Pharm. and Tech. 2020; 13(2):956-962. doi: 10.5958/0974-360X.2020.00180.8.

13. Rajalekshmi M, Shreedhara CS, Lobo R, Rao PP. The review on genetics, epigenetics, risk factors and diagnosis of colon cancer. Research Journal of Pharmacy and Technology. 2018; 11(11); 5147-5151.

14. Vivan TK, Santos CHM, Santos BM. Quality of life of patients withinflammatory bowel disease. J Coloproctol. 2017; 37(4): 279-84. doi:10.1016/j.jcol.2017.06.009.

15. Thomas Greutera Christine Manserb Valerie Pittetc Stephan R. VavrickaLuc Biedermanna on behalf of Swiss IBDnet, an official working group of theSwiss Society of Gastroenterology,Gender Differences in Inflammatory Bowel Disease. J. Digestion. 2020; 101(suppl 1):98–104.

16. Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, et al. Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology. 2018; 155(4): 1079–1089.

17. Vavricka SR, Spigaglia SM, Rogler G, PittetV,Michetti P, Felley C, et al.; Swiss IBD Cohort Study Group. Systematic evaluation of risk factors for diagnostic delay in inflammatorybowel disease. Inflamm Bowel Dis. 2012; 18(3): 496–505.

18. Malago JJ, K oninkx JF, van Dijk JE. The heat shock responseandcytoprotection of the intestinal epithelium. Cell StressChaperones. 2002; 7:191-199.

19. Klausz G, Molnár T, Nagy F, Gyulai Z, Boda K , LonovicsJ, Mándi Y. Polymorphism of the heat-shock protein geneHsp70-2, but not polymorphisms of the IL-10 and CD14 genes, is associated with the outcome of Crohn’s disease.Scand J Gastroenterol. 2005; 40:1197-204.

Received on 24.12.2022 Modified on 06.02.2023

Research J. Pharm. and Tech 2023; 16(9):4135-4137.

DOI: 10.52711/0974-360X.2023.00676